Randomized trial of adjuvant intraperitoneal alpha-interferon in stage III ovarian cancer patients who have no evidence of disease after primary surgery and chemotherapy: An intergroup study

Gynecologic Oncology

Volumn 100, Issue 1, 2006, Pages 133-138

  Alberts, David S ^a   Hannigan, Edward V ^b   Liu, Ping Yu ^c   Jiang, Caroline ^c   Wilczynski, Sharon ^d   Copeland, Larry ^e   Markman, Maurie ^f  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^c Statistical Center   (United States)

^d CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^e THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^f UNIVERSITY OF TEXAS   (United States)

Author keywords

Interferon; Intraperitoneal therapy; Ovarian neoplasms; Randomized controlled trial

Indexed keywords

ASPARTATE AMINOTRANSFERASE; CARBOPLATIN; CISPLATIN; PLATINUM; RECOMBINANT ALPHA2B INTERFERON; TAXANE DERIVATIVE;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; AGED; ALOPECIA; ANEMIA; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BIOLOGICAL THERAPY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER REGISTRY; CANCER REGRESSION; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CATHETER INFECTION; CHEMOTHERAPY INDUCED EMESIS; CHILL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG FATALITY; DRUG FEVER; DRUG INDUCED HEADACHE; DYSPNEA; FATIGUE; FEMALE; FLU LIKE SYNDROME; GRANULOCYTOPENIA; HUMAN; HYPOTENSION; INJECTION SITE REACTION; LETHARGY; LEUKOPENIA; MALAISE; MYALGIA; NAUSEA; NEUTROPENIA; OVARY CANCER; PAIN; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RIGOR; SECOND LOOK SURGERY; SENSORY NEUROPATHY; THROMBOCYTOPENIA; URINARY TRACT INFECTION;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INFUSIONS, PARENTERAL; INTERFERON-ALPHA; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS;

EID: 29144457523     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2005.07.117     Document Type: Article

References (27)

1. A. Jemal, T. Murray, E. Ward, A. Samuels, R.C. Tiwari, and A. Chafoor Cancer statistics 2005 CA Cancer J. Clin. 55 2005 10 30
2. C.M. Bagley, R.C. Young, P.S. Schein, B.A. Chabner, and V.T. DeVita Ovarian carcinoma metastatic to the diaphragm: frequently undiagnosed at laparotomy J. Obstet. Gynecol. 116 1973 397 400
3. R.F. Ozols, B.N. Bundy, B.E. Green, J.M. Fowler, D. Clarke-Pearson, and R. Burger Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group Study JCO 21 17 2003 3194 3200
4. M. Markman, P.Y. Liu, S. Wilczynski, B. Monk, L.J. Copeland, and R.D. Alvarez Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy. A Southwest Oncology Group and Gynecologic Oncology Group Trial JCO 21 13 2003 2460 2465
5. G. Bolis, A. Villa, and P. Guamerico Survival of women with advanced ovarian cancer and complete pathologic response at second-look laparotomy Cancer 77 1 1996 128 131
6. K.C. Podratz, and W.A. Cliby Second-look surgery in the management of epithelial ovarian carcinoma Obstet. Gynecol. Clin. North Am. 21 1994 155 166 [Review]
7. L.J. Copeland, L. Vaccarello, and G.S. Lewandowski Second-look laparotomy in epithelial ovarian cancer Gynecol. Oncol. 55 1994 S128 S133 [Review]
8. T. Maggino, A. Gadducci, C. Romagnolo, A. Fanucchi, and P. Fioretti Times and sites of relapses after negative second-look in advanced epithelial ovarian cancer Eur. J. Surg. Oncol. 20 2 1994 146 150
9. J.S. Berek, N.F. Hacker, A. Lichtenstein, and T. Jung Intraperitoneal recombinant α IFN for "salvage" immunotherapy in stage III epithelial ovarian cancer. A gynecologic oncology group study Cancer Res. 45 1985 4447 4453
10. L.B. Epstein, Shen Len-Ta, and J.S. Abele Sensitivity of human ovarian carcinoma cells to IFN and other antitumor agents as assessed by an in vitro semi-solid agar technique Ann. N. Y. Acad. Sci. 350 1980 228
11. N. Einhorn, K. Cantell, and S. Einhorn Human leukocyte interferon therapy for advanced ovarian cancer Am. J. Clin. Oncol. 5 1982 167
12. R.S. Freedman, J.U. Gutterman, J.T. Wharton, and F.N. Rutledge Leukocyte interferon (IFN alpha) in patients with epithelial ovarian carcinoma J. Biol. Response Modif. (US) 2 2 1983 133 138
13. G. Abdulhay, P.J. DiSaia, J.A. Blesing, and W.T. Creasman Human lymphoblastoid interferon in the treatment of advanced epithelial ovarian malignancies. A Gynecologic Oncology Group Study Am. J. Obstet. Gynecol. 152 4 1985 418 423
14. J.M. Niloff, R.C. Knapp, G. Jones, E.M. Schaetzl, and R.C. Bast Recombinant leukocyte alpha interferon in advanced ovarian carcinoma Cancer Treat Rep. 69 1985 895 896
15. M.O. Nicoletto, M.V. Fiorentino, O. Vinante, A. Prosperi, F. Tredese, and S. Tumolo Experience with intraperitoneal alpha-2 interferon Oncology 49 6 1992 467 473
16. W.P. McGuire, W.J. Hoskins, and M.E. Brady Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer N. Engl. J. Med. 334 1996 1 6
17. M.J. Piccart, K. Bertelsen, and K. James Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three year results J. Natl. Cancer Inst. 92 2000 699 702
18. F.A. Shepherd, J. Pereira, and T.E. Ciuleanu A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial J. Clin. Oncol. Proc. ASCO 22 14S 2004 7002
19. J.D. Hainsworth, J.A. Sosman, and D.R. Spigel Phase II trial of bevacizumab and erlotinib in patients with metastatic renal carcinoma (RCC) ASCO Annual Meeting Proceedings J. Clin. Oncol. vol. 22, No. 14s 2004 Abstract 4502
20. A. Nehme, A.M. Julia, and S. Jozan Modulation of cisplatin cytotoxicity by human recombinant interferon-γ in human ovarian cancer cell lines Eur. J. Cancer 30A 4 1996 520 525
21. C. Marth, A.G. Zeimet, and M. Herold Different effects of interferons, interleukin-1β and tumor necrosis factor-α in normal (OSE) and malignant human ovarian epithelial cells Int. J. Cancer 67 1996 826 830
22. R.C. Bast, T.L. Klug, and E. St. John A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer NEJM 309 1983 883 887
23. R.C. Knapp, and R.S. Berkowitz Corynebacterium parvum as an immunotherapeutic agent in an ovarian cancer model Am. J. Obstet. Gynecol. 128 1977 728
24. M.S. Mitchell, and E.L. Kanhorn Cell mediated immunity and blocking factors in ovarian cancer Obstet. Gynecol. 48 1979 590
25. I. Gresser F. Becker Cancer-A Comprehensive Treatise 1977 NU Plenum 521
26. J.M. Kirkwood, M.H. Strawderman, and M.S. Ernstorff Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684 J. Clin. Oncol. 14 1996 7 17
27. D.S. Alberts, P.Y. Liu, E.V. Hannigan, and R. O'Toole Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer N. Engl. J. Med. 335 1996 1950 1955